{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"9.9","value":"6.2"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"8.4","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.\n\nAssessed with a log-rank test stratified by whether the patient had whole pelvic radiotherapy prior to starting the study treatment. The product-limit method will be used to estimate the cumulative distribution of PFS for the patients assigned to each treatment group.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC\n\nPlacebo: Given IV","id":"OG000","title":"Arm I Gem+Doce+Placebo"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nBevacizumab: Given IV\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC","id":"OG001","title":"Arm II Gem+Doce+Bev"}],"paramType":"MEDIAN","populationDescription":"All randomized","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}